Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes With and Without Heart Failure: Analysis of the FIDELIO-DKD Study

Gerasimos Filippatos, MD, FESC, FHFA, FHFSA(h)

On behalf of B. Pitt, R. Agarwal, D. Farmakis, L.M. Ruilope, P. Rossing, J. Bauersachs, R.J. Mentz, P. Kolkhof, C. Scott, A. Joseph, G.L. Bakris, S.D. Anker, and the FIDELIO-DKD investigators



Disclosures

- Lecture Fees and/or Committee Member: Of trials/registries sponsored by Amgen, Bayer, Boehringer Ingelheim, Novartis, Medtronic, Servier, Vifor
- Research Grants: European Union
- Senior Consulting Editor: JACC: Heart Failure
- Past President: Heart Failure Association of the ESC



National and Kapodistrian University of Athens National and Kapodistrian University of Athens Attikon University Hospital, Greece



Patients with CKD, T2D and HF have a high cardiorenal risk

CKD and T2D are highly prevalent among patients with HF^{1,2}

• Patients with all three conditions have unfavourable prognosis³⁻⁵


Guidelines recommend patients with HFrEF are treated with a steroidal MRA^{6,7}

 A clear benefit of MRAs in patients with HFpEF has not been demonstrated in randomised trials⁸⁻¹⁰

Finerenone is a novel, selective, nonsteroidal MRA that blocks MR overactivation¹¹
 MR overactivation contributes to inflammation and fibrosis, which are key drivers of CKD in T2D progression¹¹


CKD, chronic kidney disease; CVD, cardiovascular disease; HF, heart failure; HFpEF, heart failure with preserved ejection fraction HFrEF, heart failure with reduced ejection fraction; LV, left ventricular; MR, mineralocorticoid receptor; MRA, mineralocorticoid receptor antagonist; T2D, type 2 diabetes
1. Anker SD, *et al. Eur Heart J* 2020;22:2383–2392; 2. Solomon SD, *et al. Circ Heart Fail* 2018;11:e004962; 3. Seferovic PM, *et al. Eur J Heart Fail* 2018;20:853–872; 4. Filippatos G, *et al. Eur Heart J* 2014;35:416–418; 5. Hsu S, *et al. Curr Opin Nephrol Hypertens* 2019;28:262–266; 6. Ponikowski P, *et al. Eur Heart J* 2016; 37:2129–2200; 7.Yancy CW, *et al. Circulation* 2013;128:e240–327;
8. Pfeffer MA, *et al. Circulation* 2015;131:34 -42; 9. Pandey A, *et al. J Am Heart Assoc* 2015;4:e002137; 10. Pitt B, *et al. N Engl J Med* 2014;370:1383–1392; 11. Agarwal R, *et al. Eur Heart J* 2021;42:152–161

FIDELIO-DKD demonstrated kidney and CV benefits with finerenone in patients with CKD and T2D



*NNT to prevent one event based on absolute risk reductions at 36 months CV, cardiovascular; NNT, number needed to treat 1. Bakris GB, *et al. N Engl J Med* 2020;383:2219–2229

FIDELIO-DKD was a global, phase III, randomized controlled trial




*10 mg if screening eGFR 25 to <60 ml/min/1.73 m²; 20 mg if ≥60 ml/min/1.73 m², up-titration encouraged from month 1 if serum potassium ≤4.8 mmol/l and eGFR stable; #defined as ESKD or an eGFR <15 ml/min/1.73 m²

; eGFR, estimated glomerular filtration rate; ESKD, end-stage kidney disease; HHF, hospitalisation for heart failure; MI, myocardial infarction; od, once daily; R, randomisation

Bakris GL, et al. N Engl J Med 2020;383:2219-2229

Patients with HFrEF were excluded in the FIDELIO-DKD trial



436 (7.7%) had a history of HF at baseline[§]

*Patients with moderately elevated albuminuria were required to also have diabetic retinopathy; #in the 30 days prior to the screening visit; ‡mean sitting SBP ≥170 mmHg or mean sitting DBP ≥110 mmHg at the run-in visit, or mean sitting SBP ≥160 mmHg or mean sitting DBP ≥100 mmHg at the screening visit; [§] history of HF defined by investigators DBP, diastolic blood pressure; HbA1c, glycated haemoglobin; NYHA, New York Heart Association; RASi, renin–angiotensin system inhibitor; SBP, systolic blood pressure; [K+], potassium concentration; UACR, urine albumin-to-creatinine ratio Bakris GL, et al. *N Engl J Med* 2020;383:2219–2229


Patients with a history of HF had a lower eGFR, higher BMI and larger waist circumference than patients without HF

Characteristic*	With history of HF (n=436) Without history of HF (n=5		
Age, years	66±9	66±9	
Gender, male, n (%)	280 (64)	3703 (71)	
Mean SBP, mmHg	138±14	138±14	
BMI, kg/m ²	33±7	31±6	
Duration of T2D, years	17±9	17±9	
HbA1c, %	7.8±1.3	7.7±1.3	
Serum [K+], mmol/l	4.4±0.5	4.4±0.5	
eGFR, ml/min/1.73 m ²	42±13	45±13	
Waist circumference, cm	111±16	106±15	
CRP, mg/l	7±13	4±9	
Heart rate, bpm	70±10	72±11	
With a history of CVD, n (%)	328 (75)	2277 (44)	

*Data expressed as mean \pm SD unless otherwise stated

BMI, body mass index; bpm, beat per minute; CRP, C-reactive protein; SBP, systolic blood pressure; SD, standard deviation

Finerenone reduced the risk of composite CV outcome* irrespective of history of HF




p-value for interaction = 0.33

*Time to CV death, nonfatal MI, nonfatal stroke, or hospitalisation for heart failure CI, confidence interval; HR, hazard ratio

The effect of finerenone on the components of the composite CV outcome was consistent across subgroups of history of HF


Endpoint	Finerenone (N=2833)	Placebo (N=2841)	Hazard ratio (95% CI)		<i>p</i> -value for interaction
	n (%)	n (%)			
Composite CV Outcome	367/2833 (13.0)	420/2841 (14.8)	к	0.86 (0.75–0.99)	
With HF	46/195 (23.6)	71/241 (29.5)	⊢ →	0.73 (0.50–1.06)	0.33
Without HF	321/2638 (12.2)	349/2600 (13.4)	⊢ → ⊢	0.90 (0.77–1.04)	
CV death	128/2833 (4.5)	150/2841 (5.3)	⊢ ⊘ +י	0.86 (0.68–1.08)	
With HF	20/195 (10.3)	22/241 (9.1)	⊢	1.11 (0.60–2.04)	0.39
Without HF	108/2638 (0.7)	128/2600 (4.9)	⊢	0.83 (0.64–1.07)	
Nonfatal MI	70/2833 (2.5)	87/2841 (3.1)	⊢ ♦ <u>+</u> •	0.80 (0.58–1.09)	
With HF	7/195 (3.6)	12/241 (5.0)	→	0.60 (0.24–1.51)	0.54
Without HF	63/2638 (2.4)	74/2600 (2.8)	⊢ → ⊢ ,	0.83 (0.60–1.17)	0.51
Nonfatal stroke	90/2833 (3.2)	87/2841 (3.1)		1.03 (0.76–1.38)	
With HF	6/195 (3.1)	6/241 (2.5)	└───	── 1.24 (0.40–3.85)	0.73
Without HF	84/2638 (3.2)	81/2600 (3.1)	⊢	1.01 (0.74–1.37)	
First HHF	139/2833 (4.9)	162/2841 (5.7)	⊢ ∽ ⊢י	0.86 (0.68–1.08)	
With HF	23/195 (11.8)	41/241 (17.0)	└──◆ ''	0.65 (0.39–1.09)	0.00
Without HF	116/2638 (4.4)	121/2600 (4.7)	⊢_	0.95 (0.73–1.22)	0.20
		0.1	25 0.25 0.5 1 2	4	
			←────	→	
			Favours finerenone Favours p	lacebo	


Finerenone slowed CKD progression irrespective of history of HF




*Kidnev failure, sustained ≥40% decrease in eGFR from baseline, or renal death


Incidence of composite outcome of CV death or HHF in the overall population was lower in finerenone-treated patients





Finerenone lowered first and total HHF events in the overall study population






A history of HF did not modify the effect of finerenone on all-cause, CV and non-CV hospitalisation

Endpoint	Finerenone	Placebo	Hazard ratio (95% CI)		<i>P</i> -value for
	n/N (%)	n/N (%)			interaction
All-cause hospitalisation	1263/2833 (44.6)	1321/2841 (46.5)	⊢ ♦ <u>−</u> 1	0.95 (0.88–1.02)	0.37
With HF	101/195 (51.8)	139/241 (57.7)		0.85 (0.66–1.10)	
Without HF	1162/2638 (44.0)	1182/2600 (45.5)	⊢ ◆−1	0.96 (0.89–1.04)	
CV hospitalisation	519/2833 (18.3)	561/2841 (19.7)		0.92 (0.82–1.04)	0.63
With HF	56/195 (28.7)	78/241 (32.4)	· · · · · · · · · · · · · · · · · · ·	0.86 (0.61–1.21)	
Without HF	463/2638 (17.6)	483/2600 (18.6)		0.94 (0.83–1.07)	
Non-CV hospitalisation	1026/2833 (36.2)	1059/2841 (37.3)		0.96 (0.88–1.05)	0.31
With HF	78/195 (40.0)	109/241 (45.2)		0.84 (0.63–1.12)	
Without HF	948/2638 (35.9)	950/2600 (36.5)		0.98 (0.90–1.07)	
		C	.5 1	2	
			Favours finerenone Favours placebo	→ o	

Incidence of overall TEAEs was similar between treatment arms irrespective of HF history



In FIDELIO-DKD, finerenone was well-tolerated and improved CV and kidney outcomes irrespective of pre-existing HF status

Finerenone consistently reduced the incidence of CV and kidney events in patients with CKD and T2D with and without a history of HF

• Due to the study design, patients with a history of HF in this analysis most likely had HFpEF

Overall, AEs were similar between treatment arms irrespective of history of HF

- In patients with a history of HF, fewer serious AEs were observed with finerenone than placebo
- There was no clinical significance in the higher incidence of hyperkalaemia with finerenone in patients with and without HF



Additional data from FIGARO-DKD and the ongoing FINEARTS-HF trial will provide the opportunity to further evaluate the efficacy and safety of finerenone in patients with HF



Thank you

FIDELIO-DKD Finerenone in reducing kiDnEy faiLure and disease progression in DKD

The FIDELIO-DKD team would like to thank all participating investigators, the centres, the sponsor study team, and the patients and their families

Executive committee

George L. Bakris (Co-chair); Gerasimos Filippatos (Co-chair); Rajiv Agarwal; Stefan D. Anker; Luis M. Ruilope; Bertram Pitt

Independent data monitoring committee

Murray Epstein; Aldo Maggioni; Glenn Chertow; Gerald DiBona; Tim Friede; Jose Lopez-Sendon; Jean Rouleau

Clinical event committee

Rajiv Agarwal; Stefan Anker; Phyllis August; Andrew Coats; Hans Diener; Wolfram Döhner; Barry Greenberg; Stephan von Haehling; James Januzzi; Alan Jardine; Carlos Kase; Sankar Navaneethan; Lauren Phillips; Piotr Ponikowski; Pantelis Sarafidis; Titte Srinivas; Turgut Tatlisumak; John Teerlink

National lead investigators

Augusto Vallejos; Richard MacIsaac; Guntram Schernthaner; Pieter Gillard; Maria Eugenia F. Canziani; Theodora Temelkova-Kurktschiev; Ellen Burgess; Sheldon Tobe; Fernando González; Zhi-Hong Liu; Andrés Ángelo' Cadena Bonfanti; Carlos Francisco Jaramillo; Martin Prazny; Peter Rossing; Jorma Strand; Michel Marre; Roland Schmieder; Christoph Wanner; Pantelis Sarafidis; Juliana Chan; László Rosivall; Joseph Eustace; Ehud Grossman; Yoram Yagil; Giuseppe Remuzzi; Daisuke Koya; Takashi Wada; Luis Alejandro Nevaréz Ruiz; Ron Gansevoort; Adriaan Kooy; Trine Finnes; Froilan De Leon; Janusz Gumprecht; Fernando Teixeira e Costa; Alexander Dreval; Anantharaman Vathsala; Aslam Amod; Sin Gon Kim; Byung Wan Lee; Julio Pascual Santos; Bengt-Olov Tengmark; Michel Burnier; Chien-Te Lee; Sukit Yamwong; Ramazan Sari; Kieran McCafferty; Borys Mankovsky; Sharon Adler; Linda Fried; Robert Toto; Mark Williams; Tran Quang Khan

48 countries, 913 sites, 13,911* participants

*Number of patients who provided informed consent